{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:56Z","timestamp":1792601636028,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,28]]},"abstract":"<jats:p>T cell\u2013engaging CD19\/CD3-bispecific BiTE Ab blinatumomab has shown an 80% complete molecular response rate and prolonged leukemia-free survival in patients with minimal residual B-lineage acute lymphoblastic leukemia (MRD+ B-ALL). Here, we report that lymphocytes in all patients of a phase 2 study responded to continuous infusion of blinatumomab in a strikingly similar fashion. After start of infusion, B-cell counts dropped to &lt; 1 B cell\/\u03bcL within an average of 2 days and remained essentially undetectable for the entire treatment period. By contrast, T-cell counts in all patients declined to a nadir within &lt; 1 day and recovered to baseline within a few days. T cells then expanded and on average more than doubled over baseline within 2-3 weeks under continued infusion of blinatumomab. A significant percentage of reappearing CD8+ and CD4+ T cells newly expressed activation marker CD69. Shortly after start of infusion, a transient release of cytokines dominated by IL-10, IL-6, and IFN-\u03b3 was observed, which no longer occurred on start of a second treatment cycle. The response of lymphocytes in leukemic patients to continuous infusion of blinatumomab helps to better understand the mode of action of this and other globally T cell\u2013engaging Abs. The trial is registered with www.clinicaltrials.gov identifier NCT00560794.<\/jats:p>","DOI":"10.1182\/blood-2012-01-400515","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T13:07:13Z","timestamp":1337260033000},"page":"6226-6233","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":424,"title":["Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab"],"prefix":"10.1182","volume":"119","author":[{"given":"Matthias","family":"Klinger","sequence":"first","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brandl","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Hijazi","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Johann Wolfgang Goethe Universit\u00e4tsklinikum, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Neumann","sequence":"additional","affiliation":[{"name":"II Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Goebeler","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum Ulm, Ulm, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Medizinische Klinik A, Universit\u00e4tsklinikum M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"II Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Johann Wolfgang Goethe Universit\u00e4tsklinikum, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Degenhard","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Nagorsen","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Baeuerle","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wolf","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kufer","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111901084079400_B1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors.","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111901084079400_B2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4049\/jimmunol.0902539","article-title":"Recent developments in cancer vaccines.","volume":"186","author":"Palucka","year":"2011","journal-title":"J Immunol"},{"issue":"6","key":"2019111901084079400_B3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/erv.11.56","article-title":"Clinical peptide vaccination trials for leukemia patients.","volume":"10","author":"Casalegno-Gardu\u00f1o","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"2019111901084079400_B4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/erv.11.74","article-title":"Melanoma vaccines: developments over the past 10 years.","volume":"10","author":"Klein","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"2019111901084079400_B5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2217\/imt.10.21","article-title":"Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.","volume":"2","author":"Page","year":"2010","journal-title":"Immunotherapy"},{"issue":"22","key":"2019111901084079400_B6","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111901084079400_B7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrc1167","article-title":"Adoptive-cell-transfer therapy for the treatment of patients with cancer.","volume":"3","author":"Dudley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2019111901084079400_B8","doi-asserted-by":"crossref","first-page":"260267","DOI":"10.1155\/2010\/260267","article-title":"Focus on adoptive T cell transfer trials in melanoma.","volume":"2010","author":"Hershkovitz","year":"2010","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"2019111901084079400_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/imt.11.18","article-title":"Current status and future applications of cellular therapies for cancer.","volume":"3","author":"Copier","year":"2011","journal-title":"Immunotherapy"},{"key":"2019111901084079400_B10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-065X.2007.00578.x","article-title":"The adaptive immune response to sporadic cancer.","volume":"220","author":"Willimsky","year":"2007","journal-title":"Immunol Rev"},{"issue":"45","key":"2019111901084079400_B11","first-page":"e2077","article-title":"Experimental metastasis and CTL adoptive transfer immunotherapy mouse model.","author":"Zimmerman","year":"2010","journal-title":"J Vis Exp"},{"issue":"3","key":"2019111901084079400_B12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3324\/haematol.10873","article-title":"Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.","volume":"92","author":"Biagi","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"2019111901084079400_B13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111901084079400_B14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"issue":"5891","key":"2019111901084079400_B15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"18","key":"2019111901084079400_B16","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111901084079400_B17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111901084079400_B18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct.","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"issue":"5","key":"2019111901084079400_B19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-005-0001-1","article-title":"T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct.","volume":"55","author":"Schlereth","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2019111901084079400_B20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol Immunol"},{"issue":"4","key":"2019111901084079400_B21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CJI.0b013e31819b7c70","article-title":"Potent control of tumor growth by CEA\/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.","volume":"32","author":"Lutterbuese","year":"2009","journal-title":"J Immunother"},{"issue":"3","key":"2019111901084079400_B22","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials.","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111901084079400_B23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12185-010-0670-1","article-title":"Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.","volume":"92","author":"Kikuchi","year":"2010","journal-title":"Int J Hematol"},{"issue":"1","key":"2019111901084079400_B24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.2011.08795.x","article-title":"Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia.","volume":"155","author":"Cazzaniga","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111901084079400_B25","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2019111901084079400_B26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.1415","article-title":"Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.","volume":"84","author":"Koopman","year":"1994","journal-title":"Blood"},{"issue":"11","key":"2019111901084079400_B27","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics.","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"issue":"6","key":"2019111901084079400_B28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"issue":"2","key":"2019111901084079400_B29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2567.2002.01447.x","article-title":"Qualitative differences between naive and memory T cells.","volume":"106","author":"Berard","year":"2002","journal-title":"Immunology"},{"issue":"2","key":"2019111901084079400_B30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.smim.2009.02.003","article-title":"Biochemical signaling pathways for memory T cell recall.","volume":"21","author":"Farber","year":"2009","journal-title":"Semin Immunol"},{"issue":"8","key":"2019111901084079400_B31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.","volume":"30","author":"Brischwein","year":"2007","journal-title":"J Immunother"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/26\/6226\/1498245\/zh802612006226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/26\/6226\/1498245\/zh802612006226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T01:08:58Z","timestamp":1574125738000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/26\/6226\/105629\/Immunopharmacologic-response-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,28]]},"references-count":31,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2012,6,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-01-400515","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,28]]}}}